[Hidradenitis suppurativa]

Area of Science:

• Dermatology
• Immunology
• Systemic Inflammatory Diseases

Background:

• Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with significant impact on quality of life.
• Despite advances in understanding, diagnosis of HS is frequently delayed, leading to disease progression and increased need for surgical interventions.
• Comorbidities associated with HS require careful consideration for comprehensive patient management.

Purpose of the Study:

• To review the current understanding of HS pathophysiology.
• To outline the established and emerging therapeutic strategies for HS management.
• To emphasize the importance of addressing risk factors and comorbidities in HS care.

Main Methods:

• Literature review of recent advancements in HS understanding and treatment.
• Analysis of current therapeutic pillars: surgery, antibiotics, and biologics.
• Discussion of risk factor modification (smoking, obesity) and comorbidity management.

Main Results:

• Improved understanding of HS pathophysiology has led to the development of new therapeutic agents.
• Current HS treatment integrates surgery, antibiotics, and biologics.
• Management strategies must address modifiable risk factors and associated comorbidities for optimal outcomes.

Conclusions:

• Effective HS management requires a multi-faceted approach, including timely diagnosis and treatment.
• Addressing risk factors like smoking and obesity, alongside managing comorbidities, is essential for individualized patient care.
• Continued research into HS pathophysiology and treatment is vital for improving patient outcomes.